Sunstone participates in EUR 39m financing round of Targed Biopharma

An investor syndicate including venture capital firm Sunstone Life Science Ventures and Norwegian Hadean ventures has injected EUR 39m into Dutch biotech company Targed Biopharmaceuticals, which develops treatments for blood-clotting disorders.

Jacob L. Moresco, investment director at Sunstone Life Science Ventures | Photo: Sunstone Life Science Ventures

Dutch biotech company Targed Biopharmaceuticals has evidently drawn attention to its treatment approach for blood-clotting disorders, also known as thrombotic diseases, as an investor syndicate has just injected EUR 39m into the company.

The syndicate included venture capital firm Sunstone Life Science Ventures, Norwegian Hadean Ventures, Andera Partners, Fund+ and Inkef Capital in addition to three existing investors in Targed Biopharma, which was founded in 2020 as a spinout from the University Medical Center Utrecht.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs